Cell News and Research

RSS

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome vaccine) clinical program in patients with non-small cell lung cancer (NSCLC) which includes the Phase III studies, STARTa and INSPIREb. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees.

17 Jun 2010

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.

17 Jun 2010

Research findings could lead to less invasive treatments for ALL

A team of researchers from the Institute for Research in Immunology and Cancer of the Universit- de Montr-al have defined for the first time the mechanism behind three cancer-causing genes in acute lymphoblastic leukemia. Published in the journal Genes and Development, the findings offer insight on the complex interaction between the genes and their contributions to leukemia, thereby providing the foundation for the design of targeted therapies.

17 Jun 2010

IRX Therapeutics raises $8M to further develop pipeline of cancer vaccine candidates

IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has raised $8 million through a note offering to existing shareholders. The new funding will be used to further develop its pipeline of cancer vaccine candidates, including its lead product, IRX-2. IRX Therapeutics has now raised a total of more than $80 million in private financing.

17 Jun 2010

FDA approves clinical testing of SanBio's SB623 for stroke recovery

SanBio Inc. announced today that the United States Food and Drug Administration (FDA) has approved the clinical testing of their SB623 regenerative medicine product in patients suffering from disability caused by cerebral stroke. SB623 is derived from bone marrow stromal cells (MSCs) isolated from healthy adult donors.

17 Jun 2010

BD Biosciences further expands Research Grant program to support promising stem cell research

BD Biosciences, a segment of BD, announced today a further expansion of its Research Grant program, adding $100,000 worth of reagents, cell culture tools and labware to support promising stem cell research.

From BD (Becton, Dickinson and Company) 17 Jun 2010

Soligenix signs common stock purchase agreements with existing and new investors

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has entered into common stock purchase agreements with both existing and new investors totaling approximately $5.16 million. Soligenix's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.

16 Jun 2010

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).

16 Jun 2010

GTC Biotherapeutics closes new $7 million secured convertible debt financing

GTC Biotherapeutics, Inc. announced the closing of a new $7 million secured convertible debt financing by its strategic partner, LFB Biotechnologies SAS, in connection with a restructuring of GTC's operations which will result in a downsizing of approximately 30 full-time positions at its headquarters and an additional 20 positions at its farm facility.

16 Jun 2010

RG7204 holds promise for metastatic melanoma with V600E BRAF mutation

Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma.

16 Jun 2010

AssureImmune merges with BCU

AssureImmune LLC, the premier family stem cell bank in the United States, today announced their merger with Banco de Cordón Umbilical, the largest cord blood bank in Latin America. This merger expands the Companies' global reach providing family stem cell banking services to North, Central and South America.

16 Jun 2010

Stress-related psychiatric disorders more common among women: Study

There may be a biological reason why depression and other stress-related psychiatric disorders are more common among women compared to men. Studying stress signaling systems in animal brains, neuroscience researchers found that females are more sensitive to low levels of an important stress hormone and less able to adapt to high levels than males.

16 Jun 2010

Life Technologies forms GIBCO Cell Therapy Systems

Life Technologies Corporation today announced the formation of GIBCO® Cell Therapy Systems (CTS™), which will offer the life science industry's widest array of products to support cell therapy applications, including regenerative medicine. Specifically designed to help cell therapy practitioners accelerate the transition from research to clinical applications, the product portfolio will include a broad and deep offering of Invitrogen devices and reagents.

16 Jun 2010

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

UCB and Immunomedics Inc. announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEM™, showed the clinical efficacy of epratuzumab in patients with SLE.

16 Jun 2010

Hamilton Thorne announces launch of Staccato multi-pulse laser system at 8th ISSCR Annual Meeting

Hamilton Thorne Ltd., a leading provider of advanced laser systems and instruments for the stem cell research and fertility clinic markets, today announced the launch of the Staccato(TM) multi-pulse laser system at the 8th Annual Meeting of the International Society of Stem Cell Research (ISSCR), June 16-19, 2010, in San Francisco, CA. Staccato(TM) will add to the functionality of the XYClone(R) laser system, providing the ability of near-continuous application of the laser to the sample through rapid pulsing of the beam.

16 Jun 2010

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday.

16 Jun 2010

Injectable bone carries living stem cells

A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.

16 Jun 2010

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

ProBioGen AG announced today that Minapharm Pharmaceuticals, Cairo, has completed the acquisition of 95 % of the share capital of ProBioGen, an internationally renowned German cell line development and contract manufacturing specialist. The total purchase price of EUR 30.4 million includes earn-out payments which are conditional upon the achievement of defined milestones.

16 Jun 2010

Study demonstrates mechanism behind hijacking of TNF controlled response to tumours

Cancer Research UK scientists have discovered how two genes can 'hijack' control of part of the body's defences against cancer, helping them grow and spread.

16 Jun 2010

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Acclaimed virologist Robert Webster, Ph.D., of St. Jude Children's Research Hospital, presented the 2010 Leeuwenhoek prize lecture today, a prestigious recognition awarded by the Royal Society in London.

16 Jun 2010

Cell News and Research

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

Research findings could lead to less invasive treatments for ALL

IRX Therapeutics raises $8M to further develop pipeline of cancer vaccine candidates

FDA approves clinical testing of SanBio's SB623 for stroke recovery

BD Biosciences further expands Research Grant program to support promising stem cell research

Soligenix signs common stock purchase agreements with existing and new investors

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

GTC Biotherapeutics closes new $7 million secured convertible debt financing

RG7204 holds promise for metastatic melanoma with V600E BRAF mutation

AssureImmune merges with BCU

Stress-related psychiatric disorders more common among women: Study

Life Technologies forms GIBCO Cell Therapy Systems

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

Hamilton Thorne announces launch of Staccato multi-pulse laser system at 8th ISSCR Annual Meeting

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

Injectable bone carries living stem cells

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

Study demonstrates mechanism behind hijacking of TNF controlled response to tumours

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

How to optimize your cell line development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics